Renal protective effect of YM598, a selective endothelin ET(A) receptor antagonist, against diabetic nephropathy in OLETF rats (Q44121983)

30 November 2017

title

Renal protective effect of YM598, a selective endothelin ET(A) receptor antagonist, against diabetic nephropathy in OLETF rats (English)

1 reference

30 November 2017

1 reference

Koh-ichi Sugimoto

1

1 reference

30 November 2017

Shuichi Tsuruoka

series ordinal

2

1 reference

30 November 2017

Akio Fujimura

series ordinal

3

1 reference

30 November 2017

language of work or name

English

0 references

publication date

1 August 2002

1 reference

European Journal of Pharmacology

30 November 2017

published in

1 reference

30 November 2017

volume

450

1 reference

30 November 2017

issue

2

1 reference

30 November 2017

page(s)

183-189

1 reference

Urinary endothelin: a possible biological marker of renal damage

30 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902006-X

Unselective inhibition of endothelin receptors reduces renal dysfunction in experimental diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902006-X

Endothelin antagonists and renal protection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902006-X

Evaluation of glomerular lesion and abnormal urinary findings in OLETF rats resulting from a long-term diabetic state

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902006-X

High urinary excretion of glycosaminoglycans: a possible marker of glomerular involvement in diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902006-X

Synthesis and structure-activity relationships in a series of ethenesulfonamide derivatives, a novel class of endothelin receptor antagonists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902006-X

Serum and urinary concentrations of type IV collagen and laminin as a marker of microangiopathy in diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902006-X

Renal Endothelin System in Diabetes: Comparison of Angiotensin-Converting Enzyme Inhibition and Endothelin-A Antagonism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902006-X

Endothelin: emerging role in diabetic vascular complications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902006-X

Endothelin receptor subtype B mediates autoinduction of endothelin-1 in rat mesangial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902006-X

Urinary type IV collagen as a marker for early diabetic nephropathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902006-X

Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902006-X

Increased urinary endothelin-1-like immunoreactivity excretion in NIDDM patients with albuminuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902006-X

Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902006-X

Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902006-X

Urinary excretion of endothelin-1 in normal subjects and patients with renal disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902006-X

An endothelin-1 mediated autocrine growth loop involved in human renal tubular regeneration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902006-X

Protection of kidney function and decrease in albuminuria by captopril in insulin dependent diabetics with nephropathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902006-X

Endothelin-1 stimulates its own synthesis in human endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902006-X

The correlation of plasma and urine endothelin-1 with the severity of nephropathy in Chinese patients with type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902006-X

Hyperlipidaemia and the progression of nephropathy in OLETF rats: effect of angiotensin-converting enzyme inhibitor, enalapril

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902006-X

Captopril reduces the risk of nephropathy in IDDM patients with microalbuminuria. The Microalbuminuria Captopril Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902006-X

A spectrophotometric method for the determination of heparan sulfate.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902006-X

Increased renal excretion of endothelin-1 in nephrotic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902006-X

Enhanced secretion of endothelin-1 by elevated glucose levels from cultured bovine aortic endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902006-X

Proximal tubular cell synthesis and secretion of endothelin-1 on challenge with albumin and other proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902006-X

10.1016/S0014-2999(02)02006-X

7 January 2021

Identifiers

DOI

1 reference

30 November 2017

1 reference